Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 12/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.51 |
| ▸ | SLC8A1 | P32418 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
| ▸ | HTR1A | P08908 | 2/20 | 0.34 |
| ▸ | HTR7 | P34969 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18525051 | 1.00 | SLC6A9 (0.57) | SLC6A9KCNH2SLC8A1ALDH1A1HPGD | |
| SCHEMBL14682235 | 0.98 | SLC6A9 (0.55) | SLC6A9KCNH2SLC8A1ALDH1A1HPGD | |
| SCHEMBL18525062 | 0.98 | SLC6A9 (0.55) | SLC6A9KCNH2SLC8A1ALDH1A1HPGD | |
| SCHEMBL14682183 | 0.86 | SLC6A9 (0.77) | SLC6A9KCNH2SLC8A1HTR1AHTR7 | |
| SCHEMBL18525094 | 0.86 | SLC6A9 (0.77) | SLC6A9KCNH2SLC8A1HTR1AHTR7 | |
| SCHEMBL14673536 | 0.86 | SLC6A9 (0.44) | SLC6A9KCNH2SLC8A1ALDH1A1HPGD | |
| SCHEMBL607648 | 0.86 | SLC6A9 (0.62) | SLC6A9KCNH2SLC8A1HRH3HTR1A | |
| SCHEMBL14673537 | 0.86 | SLC6A9 (0.44) | SLC6A9KCNH2SLC8A1ALDH1A1HPGD | |
| SCHEMBL14673067 | 0.86 | SLC6A9 (0.44) | SLC6A9KCNH2SLC8A1ALDH1A1HPGD | |
| SCHEMBL14673066 | 0.86 | SLC6A9 (0.44) | SLC6A9KCNH2SLC8A1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2739614-B1 | AMINOCHROMANEs, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE DEUTSCHLAND (DE) | 2017-02-22 | — | — | EP | disclosed |
| US-8853196-B2 | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-10-07 | — | — | US | disclosed |
| US-8853196-B2 | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-10-07 | — | — | US | disclosed |
| WO-2013020930-A1 | AMINOCHROMANE, AMINOTHIOCHROMANE AND AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2013-02-14 | — | — | WO | disclosed |
| US-20130035323-A1 | AMINOCHROMANE, AMINOTHIOCHROMANE AND AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2013-02-07 | — | — | US | disclosed |
| US-20130035323-A1 | AMINOCHROMANE, AMINOTHIOCHROMANE AND AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2013-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035323-A1 | AMINOCHROMANE, AMINOTHIOCHROMANE AND AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | SLC7A1, BCAT1, AADAT | SLC6A9 189/4885KCNH2 1393/4885SLC8A1 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.